Bunse C E, Fortmeier V, Tischer S, Zilian E, Figueiredo C, Witte T, Blasczyk R, Immenschuh S, Eiz-Vesper B
Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany; Integrated Research and Treatment Centre Transplantation - IFB-Tx, Hannover Medical School, Hannover, Germany.
Clin Exp Immunol. 2015 Feb;179(2):265-76. doi: 10.1111/cei.12451.
Heme oxygenase (HO)-1, the inducible isoform of HO, has immunomodulatory functions and is considered a target for therapeutic interventions. In the present study, we investigated whether modulation of HO-1 might have regulatory effects on in-vitro T cell activation. The study examined whether: (i) HO-1 induction by cobalt-protoporphyrin (CoPP) or inhibition by tin-mesoporphyrin (SnMP) can affect expansion and function of virus-specific T cells, (ii) HO-1 modulation might have a functional effect on other cell populations mediating effects on proliferating T cells [e.g. dendritic cells (DCs), regulatory T cells (T(regs)) and natural killer cells] and (iii) HO-1-modulated anti-viral T cells might be suitable for adoptive immunotherapy. Inhibition of HO-1 via SnMP in cytomegalovirus (CMV)pp65-peptide-pulsed peripheral blood mononuclear cells (PBMCs) led to increased anti-viral T cell activation and the generation of a higher proportion of effector memory T cells (CD45RA(-) CD62L(-)) with increased capability to secrete interferon (IFN)-γ and granzyme B. T(reg) depletion and SnMP exposure increased the number of anti-viral T cells 15-fold. To test the possibility that HO-1 modulation might be clinically applicable in conformity with good manufacturing practice (GMP), SnMP was tested in isolated anti-viral T cells using the cytokine secretion assay. Compared to control, SnMP treatment resulted in higher cell counts and purity without negative impact on quality and effector function [CD107a, IFN-γ and tumour necrosis factor (TNF)-α levels were stable]. These results suggest an important role of HO-1 in the modulation of adaptive immune responses. HO-1 inhibition resulted in markedly more effective generation of functionally active T cells suitable for adoptive T cell therapy.
血红素加氧酶(HO)-1是HO的诱导型同工酶,具有免疫调节功能,被视为治疗干预的靶点。在本研究中,我们调查了HO-1的调节是否可能对体外T细胞活化具有调节作用。该研究考察了:(i)钴原卟啉(CoPP)诱导HO-1或锡中卟啉(SnMP)抑制HO-1是否会影响病毒特异性T细胞的扩增和功能,(ii)HO-1调节是否可能对介导对增殖T细胞产生影响的其他细胞群体[如树突状细胞(DC)、调节性T细胞(Tregs)和自然杀伤细胞]具有功能作用,以及(iii)HO-1调节的抗病毒T细胞是否可能适用于过继性免疫治疗。在巨细胞病毒(CMV)pp65肽脉冲的外周血单个核细胞(PBMC)中,通过SnMP抑制HO-1导致抗病毒T细胞活化增加,并产生更高比例的效应记忆T细胞(CD45RA(-)CD62L(-)),其分泌干扰素(IFN)-γ和颗粒酶B的能力增强。Treg耗竭和SnMP暴露使抗病毒T细胞数量增加了15倍。为了测试HO-1调节可能符合药品生产质量管理规范(GMP)临床应用的可能性,使用细胞因子分泌试验在分离的抗病毒T细胞中测试了SnMP。与对照相比,SnMP处理导致细胞计数更高且纯度更高,而对质量和效应功能没有负面影响[CD107a、IFN-γ和肿瘤坏死因子(TNF)-α水平稳定]。这些结果表明HO-1在适应性免疫反应调节中起重要作用。HO-1抑制导致明显更有效地产生适用于过继性T细胞治疗的功能活性T细胞。